

Brandes Investment Partners
U.S. Value Equity Strategy Notes
Second Quarter 2025 (1 April – 30 June 2025)

The Brandes U.S. Value Equity Strategy rose 2.22% (gross of fees) in the quarter, underperforming its benchmark, the Russell 1000 Value Index, which was up 3.79%.

Contributors to Performance

The largest contributors to performance reflected a combination of solid stock selection in the technology and health care sectors. Electronics manufacturing services provider Flex continued to capitalise on robust demand across its diversified manufacturing services platform. Semiconductor firm Micron Technology also contributed positively, supported by improving memory chip pricing and strong AI-related demand. The company's leadership in DRAM and NAND technologies continues to position it well for long-term growth.

Within health care, Cardinal Health advanced on the back of continued margin expansion and upward earnings revisions. Other contributors included agricultural chemicals firm Corteva and commercial bank Citigroup. Corteva benefited from improving agricultural fundamentals and pricing power in its seed and crop protection businesses, while Citigroup rose as a steepening yield curve, the expectation of deregulation, and an improved capital return outlook boosted investor sentiment. The market also responded positively to the bank's capital discipline and restructuring progress.

Detractors from Performance

The largest detractors from performance were concentrated in energy and communication services. Shares of both Chevron and Halliburton retreated amid falling energy prices and investor concerns around global demand. Advertising agency Omnicom also declined due to concerns about integration risk and dilution following its announced stock-for-stock acquisition deal with Interpublic Group.

Other notable detractors included financial technology holding Fiserv, chemicals firm Westlake, and insurer Willis Towers Watson.

Fiserv faced weakened investor sentiment following a slowdown in its small business gross merchandise volume in the first quarter of 2025. Despite the slowing near-term growth, Fiserv remains well positioned, in our opinion, to grow at an attractive rate over the next several years. We believe Fiserv should benefit from improving profitability as it scales. This, coupled with the company's share repurchase program, supports our belief in Fiserv as a high-quality compounder with durable earnings power.

Westlake experienced margin pressure as it suffered from oversupply in its commodity chemicals segment, as well as weaker housing-related demand in its building materials segment. Meanwhile, Willis Towers Watson underperformed as softer-than-expected organic growth and margin compression in its consulting business weighed on results.

Portfolio Activity

We initiated new positions in healthcare companies Becton Dickinson and ICON as well as retailer, Target Corporation, while exiting General Dynamics, Berkshire Hathaway, and Cisco.

Becton Dickinson (BDX) is one of the world's largest medical device manufacturers with the top U.S. market share in medication delivery, diagnostics, and interventional products. About 85% of BDX's revenues are recurring, and the company benefits from deep integration into hospital networks, a broad product portfolio, and scale advantages in manufacturing. Since the launch of its transformation plan in 2021, BDX has focused on organic growth, margin expansion, and deleveraging. A pending divestiture of its Biosciences and Diagnostic Solutions businesses could potentially unlock value, and in our view, BDX offers a compelling combination of quality, stability, and upside optionality from product portfolio optimisation.

ICON is a leading global clinical research organisation (CRO), offering a full suite of services for the pharmaceutical industry across the clinical development cycle, including trial design, execution, post-market commercialisation, and data solutions. Following its acquisition of PRA Health in 2021, ICON became the largest pure-play CRO, with 16%

share of the global clinical outsourcing market. The company boasts a vast clinical site network that allows fast patient recruitment.

ICON has been out of favor as the CRO industry faces slowing growth due to already high outsourcing penetration and cyclical headwinds from reduced biotech funding. However, we believe ICON is well equipped to navigate these challenges given its healthy balance sheet and solid competitive positioning. Additionally, with deleveraging from the PRA acquisition now complete, ICON can utilise its capital to fund future growth (e.g., by consolidating weaker players) and share buybacks. We see ICON as an attractive value opportunity, with the stock trading at less than 11x price/earnings.

The exits from General Dynamics, Berkshire Hathaway, and Cisco were valuation-driven, as each company approached or exceeded our estimates of intrinsic value. We redeployed the capital into higher-conviction opportunities that offer what we consider more attractive risk/reward profiles.

Year-to-Date Briefing

The Brandes U.S. Value Equity Strategy gained 6.45% (gross of fees), outperforming the Russell 1000 Value Index, which rose 6.00% for the six months ended 30 June 2025.

Leading contributors included holdings in health care and technology, such as Flex and Micron, as well as pharmaceutical distributors McKesson and Cardinal Health. Another notable contributor from the quarter, Corteva, was also among the standout performers for the year.

Major detractors included holdings in industrials and communication services, notably FedEx, ad agency Omnicom, and Alphabet. Pharmaceutical firm Merck also hurt performance, along with oil services company Halliburton and chemical company Westlake.

Current Positioning

Although there has been significant portfolio activity amid the volatile market environment this year, portfolio exposure from a sector perspective remains largely unchanged. Overall, the portfolio continues to have overweight positions in financials and health care, while maintaining key underweights in real estate and utilities. We have pared allocations to some of the strong-performing areas of the market (e.g., financials and technology), while adding to others that have underperformed (e.g., health care).

In the second quarter, the valuation gap between value and growth stocks (MSCI USA Value vs. MSCI USA Growth) widened again, driven by a rebound in technology stocks, which accounted for over 50% of the growth index as of June 30. We are increasingly optimistic about the return potential for value stocks over the longer term and the diversification benefits they offer in a concentrated U.S. market. Currently, value stocks are trading at the largest quartile discount relative to growth stocks since the inception of the style indices. This valuation disparity is evident across various metrics, such as price/earnings, price/cash flow, and enterprise value/sales. Historically, such valuation differentials have often signaled compelling subsequent returns for value stocks over longer-term horizons. This is encouraging to us because our portfolio, guided by our value philosophy and process, has tended to outperform the Russell 1000 Value benchmark when the benchmark has outperformed the broader Russell 1000 Index. We believe the differences between the strategy and the broad U.S. market index make it an excellent complement and diversifier to passive and growth-oriented strategies.

As of 30 June, the Brandes U.S. Value Equity Strategy trades at more compelling valuation levels than the benchmark, in our opinion. We believe the current fundamentals of our holdings bode well for the long term, and we are excited about the strategy's prospects.

Term definitions: <https://www.brandes.com/termdefinitions>

The Russell 1000 Index with gross dividends measures performance of the large cap segment of the U.S. equity universe.

The Russell 1000 Value Index with gross dividends measures performance of the large cap value segment of the U.S. equity universe. Securities are categorised as growth or value based on their relative book-to-price ratios, historical sales growth, and expected earnings growth.

The Russell 1000 Growth Index with gross dividends measures performance of the large cap growth segment of the U.S. equity universe. Securities are categorised as growth or value based on their relative book-to-price ratios, historical sales growth, and expected earnings growth.

The MSCI USA Value Index captures large and mid cap U.S. securities exhibiting overall value style characteristics, defined using book value to price, 12-month forward earnings to price, and dividend yield.

The MSCI USA Growth Index captures large and mid cap U.S. securities exhibiting overall growth style characteristics, defined using long-term forward earnings per share (EPS) growth rate, short-term forward EPS growth rate, current internal growth rate, long-term historical EPS growth trend, and long-term historical sales per share growth trend.

MSCI has not approved, reviewed or produced this report, makes no express or implied warranties or representations and is not liable whatsoever for any data in the report. You may not redistribute the MSCI data or use it as a basis for other indices or investment products.

Diversification does not assure a profit or protect against a loss in a declining market.

The foregoing Quarterly Commentary reflects the thoughts and opinions of Brandes exclusively and is subject to change without notice. The information provided in the commentary should not be considered a recommendation to purchase or sell any particular security. It should not be assumed that any security transactions, holdings or sectors discussed were or will be profitable, or that the investment recommendations or decisions we make in the future will be profitable or will equal the investment performance discussed herein. International and emerging markets investing is subject to certain risks such as currency fluctuation and social and political changes; such risks may result in greater share price volatility. There is no assurance that any securities discussed herein will remain in an account's portfolio at the time you receive this report or that the securities sold have not been repurchased. The actual characteristics with respect to any particular account will vary based on a number of factors including but not limited to: (i) the size of the account; (ii) investment restrictions applicable to the account, if any; and (iii) market exigencies at the time of investment. Unlike bonds issued or guaranteed by the U.S. government or its agencies, stocks and other bonds are not backed by the full faith and credit of the United States. Stock and bond prices will experience market fluctuations. Please note that the value of government securities and bonds in general have an inverse relationship to interest rates. Bonds carry the risk of default, or the risk that an issuer will be unable to make income or principal payment. There is no assurance that private guarantors or insurers will meet their obligations. The credit quality of the investments in the portfolio is not a guarantee of the safety or stability of the portfolio. Investments in Asset Backed and Mortgage Backed Securities include additional risks that investors should be aware of such as credit risk, prepayment risk, possible illiquidity and default, as well as increased susceptibility to adverse economic developments. Securities of small companies generally experience more volatility than mid and large sized companies. Although the statements of fact and data in this report have been obtained from, and are based upon, sources that are believed to be reliable, we cannot guarantee their accuracy, and any such information may be incomplete or condensed. Strategies discussed are subject to change at any time by the investment manager in its discretion due to market conditions or opportunities. The Brandes investment approach tends to result in portfolios that are materially different than their benchmarks with regard to characteristics such as risk, volatility, diversification, and concentration. Please note that all indices are unmanaged and are not available for direct investment. Past performance is not a guarantee of future results. No investment strategy can assure a profit or protect against loss. Market conditions may impact performance. The performance results presented were achieved in particular market conditions which may not be repeated. Moreover, the current market volatility and uncertain regulatory environment may have a negative impact on future performance. The margin of safety for any security is defined as the discount of its market price to what the firm believes is the intrinsic value of that security. The declaration and payment of shareholder dividends are solely at the discretion of the issuer and are subject to change at any time.

Ireland/Europe: FOR PROFESSIONAL INVESTOR USE ONLY. Issued by Brandes Investment Partners (Europe) Limited (Brandes Europe), Alexandra House, The Sweepstakes, Ballsbridge, Dublin, D04 C7H2, Ireland. Registered in Ireland Number 510203. Authorised and regulated by the Central Bank of Ireland. This report is being provided for information purposes only, no representation or warranty is made, whether express or implied as to the accuracy or completeness of the information provided. To the fullest extent permitted by law Brandes Europe shall not be liable for any loss or damage suffered by any person as a result of the receipt of this report. Recipients of this report should obtain their own professional advice. The distribution of this report may be restricted by law. No action has been or will be taken by Brandes Europe to permit the possession or distribution of this report in any jurisdiction where action for that purpose may be required. Accordingly, this report may not be used in any jurisdiction except under circumstances that will result in compliance with any applicable laws and regulations. Persons to whom this report is communicated should inform themselves about and observe any such restrictions. This information is being issued only to, and/or is directed only at (i) persons who have professional experience in matters relating to investments or (ii) are persons falling within Article 49(2)(a) to (d) ("high net worth companies, unincorporated associations etc.") of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 or to whom it may otherwise lawfully be communicated (all such persons together being referred to as "Relevant Persons"). This communication must not be acted on or relied on by persons who are not Relevant Persons. Any investment or investment activity to which this communication relates is available only to Relevant Persons and will be engaged in only with Relevant Persons. This report is a confidential communication to, and solely for the use of, the persons to whom it is distributed to by Brandes Europe.